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Available online 30 July 2016Using 3D organotypic rat brain cell cultures in aggregates we recently identiﬁed 2-methylcitrate (2-MCA) as the
main toxic metabolite for developing brain cells in methylmalonic aciduria. Exposure to 2-MCA triggered mor-
phological changes and apoptosis of brain cells. This was accompanied by increased ammonium and decreased
glutamine levels. However, the sequence and causal relationship between these phenomena remained unclear.
To understand the sequence and time course of pathogenic events,we exposed 3D rat brain cell aggregates to dif-
ferent concentrations of 2-MCA (0.1, 0.33 and 1.0mM) fromday in vitro (DIV) 11 to 14. Aggregateswere harvest-
ed at different time points from DIV 12 to 19. We compared the effects of a single dose of 1 mM 2-MCA
administered on DIV 11 to the effects of repeated doses of 1 mM 2-MCA. Pan-caspase inhibitors Z-VAD FMK or
Q-VD-OPh were used to block apoptosis.
Ammonium accumulation in the culture medium started within few hours after the ﬁrst 2-MCA exposure. Mor-
phological changes of the developing brain cells were already visible after 17 h. The highest rate of cleaved cas-
pase-3 was observed after 72 h. A dose-response relationship was observed for all effects. Surprisingly, a single
dose of 1 mM 2-MCA was sufﬁcient to induce all of the biochemical and morphological changes in this model.
2-MCA-induced ammonium accumulation and morphological changes were not prevented by concomitant
treatment of the cultures with pan-caspase inhibitors Z-VAD FMK or Q-VD-OPh: ammonium increased rapidly
after a single 1 mM 2-MCA administration even after apoptosis blockade.
We conclude that following exposure to 2-MCA, ammoniumproduction in brain cell cultures is an early phenom-
enon, preceding cell degeneration and apoptosis, and may actually be the cause of the other changes observed.
The fact that a single dose of 1 mM 2-MCA is sufﬁcient to induce deleterious effects over several days highlights
the potential damaging effects of even short-lasting metabolic decompensations in children affected by
methylmalonic aciduria.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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sen).
. This is an open access article undermutase (EC 5.4.99.2). This enzyme is involved in the catabolic pathways
of branched-chain amino acids, pyrimidines, odd-chain fatty acids and
cholesterol side-chains [1–3]. This enzymatic dysfunction provokes
the accumulation of putative toxic compounds proximal to the enzy-
matic block in body tissues and ﬂuids, mainly methylmalonic acid
(MMA), propionic acid and 2-methylcitrate (2-MCA) [4].
Neurologic complications are a major concern in MMAuria, as they
can be severe and result in a permanent handicap [5,6]. Movement dis-
orders, seizures and mental retardation are the main neurologic symp-
toms [7]. The characteristic bilateral lesion of basal ganglia usually
occurs during episodes of metabolic decompensation [1]. The patholog-
ical mechanisms responsible for the neurologic deterioration in
MMAuria are still poorly understood.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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generation in MMAuria relies on two hypotheses: the “toxic metabolite
hypothesis” suggests that metabolites accumulating in MMAuria are
toxic for the central nervous system (CNS) [8,9]. The second hypothesis,
“the trapping hypothesis”, proposes that these putatively toxic metabo-
lites are trapped and accumulate in the brain because of a limited ﬂux
out of the CNS through the blood-brain barrier [10]. Moreover, it is
also thought that the metabolites are autonomously produced in the
brain due to the presence of the metabolic defect in neurons [11]. As a
consequence, these metabolites reach very high concentrations in the
CNS leading to brain damage [8].
Based on these two hypotheses, the toxic role of the metabolites ac-
cumulating in MMAuria was investigated. Studies have mainly focused
on the neurotoxicity of MMA, until it was suggested thatMMAmight be
neurotoxic synergistically with propionyl-CoA and 2-MCA [12]. Alto-
gether, these studies suggest that impairment of mitochondrial energy
metabolism, secondary excitotoxicity and oxidative stress contribute
to the pathogenesis of MMAuria [13–20].
3D organotypic brain cell aggregates derived from rat embryos are
highly organized cultures resembling the in vivo developing brain struc-
ture and functions. They display great advantages for the study of in-
born errors of metabolism affecting the CNS as they contain all types
of brain cells and allow the study of different stages of brain develop-
ment [21–23]. We previously developed an in vitromodel of MMAuria
in brain cell aggregates, by exposing these cultures to the different me-
tabolites accumulating in this disease [24]. Our previous work in 3D ag-
gregates indicated 2-MCA as the most toxic metabolite. Besides
MMAuria, 2-MCA is known to accumulate in propionic aciduria and to
a lesser extent in cobalamine and biotin deﬁciencies. Administration
of 2-MCA altered the morphology of astrocytes, oligodendrocytes and
neurons and increased cell death by apoptosis. Furthermore, ammoni-
um (NH4+) levels in culture medium increased while glutamine levels
decreased after administration of 2-MCA [24]. Theseﬁndingswere pres-
ent at day in vitro (DIV) 14. However, the starting time of these events
and their chronological order were unknown.
Based on our recent results, this study examined the time course of
previously observed effects induced by 2-MCA in 3D brain cell aggre-
gates and followed these aggregates over a longer period of time than
in our previous study. We also administered the pan-caspase inhibitors
Z-VAD FMK and Q-VD-OPh in some cultures to prevent apoptosis in
order to identify the events related to caspase activation. Moreover,
we investigated the effects of a single dose of 1 mM 2-MCA compared
to repeated applications of 1 mM 2-MCA.
2. Material and methods
2.1. Ethics statement
This studywas carried out in strict accordance with the Ethical Prin-
ciples and Guidelines for Scientiﬁc Experiments on Animals of the Swiss
Academy forMedical Sciences. The protocol was approved by the Ethics
Committee for Animal Experimentation. The rats had sufﬁcient amount
of food and water during the transportation period and before their
sacriﬁce.
2.2. 3D organotypic rat brain cell cultures in aggregates
Pregnant Sprague–Dawley rats (Charles-River, France) were
sacriﬁced by decapitation on day 15 of gestation. The decapitation was
followed by removal of embryos. Fetal whole brains were extracted,
pooled and mechanically dissociated. 3.6 × 107 cells were grown in
8 ml of a serum-free, chemically-deﬁned medium with 25 mM glucose
and maintained under constant gyratory agitation at 37 °C, in an atmo-
sphere of 10% CO2 and 90% humidiﬁed air to form reaggregated 3D pri-
mary brain cell cultures as previously described [25,26]. Media were
replenished every three days from DIV 5 until DIV 14, and every twodays from DIV 14 on, by exchanging 5 ml of medium per culture.
When culturemedia were removed theywere kept at−80 °C until bio-
chemical analysis. On the day of harvest, aggregate pellets werewashed
three times with ice-cold phosphate-buffered saline (PBS) and either
embedded for histology in embedding compound (Tissue-Tek O.C.T.
Compound, Sakura Finetek, Netherlands) and frozen in liquid nitro-
gen-cooled 2-methylbutane (Sigma-Aldrich, Germany), or directly fro-
zen in liquid nitrogen and kept at−80 °C until analysis.
2.3. Treatment protocols
Themetabolite 2-MCA (Ernesto Brunet-Romero, Madrid, Spain)was
buffered in PBS and the pHwas adjusted to 7.5. Cultureswere grown ac-
cording to three different protocols (Fig. 1A–C). In protocol A, cultures
were treated with 0.1, 0.33 or 1 mM 2-MCA 6 times every 12 h from
DIV 11 to DIV 14; aggregates were harvested 5 h after the treatment
on DIV 12, 13, 14, 15, 17 and 19. In protocol B, cultures were treated
with a single dose of 1 mM2-MCA on DIV 11; aggregates were harvest-
ed on DIV 14 and 15. In protocol C, the pan-caspase inhibitors Z-VAD
FMK (Enzo Life Sciences, USA) or Q-VD-OPh (Sigma-Aldrich, Germany)
were added to 2-MCA-treated cultures and controls.
Z-VAD FMK was solubilized in dimethyl sulfoxyde (DMSO, Sigma-
Aldrich, Germany) and further diluted in culture medium, leading to a
ﬁnal concentration of 0.2% DMSO in culture ﬂask. Z-VAD FMK was
added at a ﬁnal concentration of 100 μM per culture ﬂask on DIV 11 in
controls and 1 mM 2-MCA-treated cultures (Fig. 1C1). Q-VD-OPh was
solubilized in DMSO and further diluted in culture medium, leading to
a ﬁnal concentration of 0.05% DMSO in culture ﬂask. Q-VD-OPh was
added at a ﬁnal concentration of 10 μM per culture ﬂask on DIV 11 in
controls and 1 mM 2-MCA-treated cultures (Fig. 1C2). DMSO alone
was also treated as control condition to verify its potential toxicity for
the aggregates. Aggregates and culture medium were harvested on
DIV 14 as previously described.
2.4. Immunoﬂuorescence
Immunoﬂuorescence was carried out on 16 μm aggregate cryosec-
tions using antibodies against different markers of brain cell types. All
antibodies used in this study were commercially available and raised
against the following antigens: GalC (mouse monoclonal anti-
galactocerebroside, 1:100, Millipore, MAB342); GFAP (mousemonoclo-
nal anti-glial ﬁbrillary acidic protein, 1:100,Millipore,MAB360); p-NFM
(mouse monoclonal anti-medium weight phosphorylated neuroﬁla-
ment 160 kDa, clone NN18, 1:200, Millipore, MAB5254); MBP (mouse
monoclonal anti-myelin basic protein, 1:100, Santa Cruz Biotechnology,
Inc., sc-66064). Secondary antibodies were goat anti-mouse IgG labeled
with Alexa Fluor® 555 (red), chicken anti-mouse IgG labeledwith Alexa
Fluor® 488 (green) or donkey anti-goat IgG labeled with Alexa Fluor®
488 (green). Sections were ﬁxed for 1 h in 4% paraformaldehyde
(Sigma-Aldrich, Germany) in PBS at room temperature and washed in
PBS (3 × 5 min). Non-speciﬁc antibody binding sites were blocked
with 1% bovine serum albumin in PBS (BSA-PBS; Sigma-Aldrich, Germa-
ny) for 1 h. Primary antibodies diluted in 1% BSA-PBS were applied to
sections and further detected with the corresponding secondary
antibodies.
Labeling of microglia with Isolectin IB4 Alexa Fluor® 568 dye conju-
gate (I21412, Invitrogen, USA) was proceeded as above-mentioned, but
the secondary antibody was omitted.
Detection of cleaved caspase-3 (rabbit polyclonal anti-cleaved Cas-
pase-3, Asp175, 1:1000, Cell Signaling, 9661) in aggregates was per-
formed with the Tyramide Signal Ampliﬁcation Kit (Life Technologies,
USA). Aggregate cryosections (16 μm) were subjected to the same pro-
cedure as described above. In addition, endogenous peroxidase activity
was quenchedwith 1.5% H2O2 in PBS (Sigma-Aldrich, Germany) follow-
ed by washes with PBS (3 × 5min). Non-speciﬁc antibody binding sites
were blocked for 1 h at room temperature with the blocking buffer of
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Fig. 1. Treatment protocols. Brain cell aggregates were treated and harvested according to three different protocols: (A) Different concentrations of 2-MCA (0.1/0.33/1 mM) were
administered six times, from DIV 11 to 14, every 12 h. Aggregates were harvested on DIV 12, 13, 14, 15, 17 and 19. (B) A single dose of 1 mM 2-MCA was administered on DIV 11.
Aggregates were harvested on DIV 14 and 15. (C) 1 mM 2-MCA was administered six times, from DIV 11 to 14, every 12 h. Additionally, 0.1 mM Z-VAD FMK (C1) or 0.01 mM Q-VD-
OPh (C2) was administered on DIV 11 to inhibit apoptosis. Aggregates were harvest on DIV 14.
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cleaved caspase-3 (Cell Signaling Technology, USA) diluted 1:1000 in
blocking buffer was applied to sections overnight at 4 °C. After washing,
sectionswere incubatedwith a horseradish peroxidase (HRP) conjugat-
ed anti-rabbit IgG secondary antibody (provided by the kit) for 1 h. Per-
oxidase staining was performed using Alexa Fluor® 555-labeled
tyramide diluted 1:200 in ampliﬁcation buffer (provided by the kit)
and applied to sections for 10 min. Negative controls were processed
the same but omitting the primary antibody, resulting in no staining.
Sections were then mounted under FluorSave™ (Merck Millipore,
Germany), observed and photographed using an Olympus BX50 micro-
scope equipped with a UC30 digital camera (Olympus, Japan).
2.5. Western blot analyses
Aggregates were homogenized in 150 mM sodium chloride, 50 mM
Tris–HCl, pH 8.0, 1% NP-40 (Sigma-Aldrich, Germany) and Protease In-
hibitor Cocktail - Complete Mini (Roche Applied Science, Switzerland),
and sonicated for 5 s. Lysates were cleared by centrifugation at
12,000 rpm for 30 min at 4 °C.
After dilution, the protein content was measured by bicinchoninic
acid assay (Thermo Scientiﬁc, USA) and diluted to a ﬁnal concentration
of 1.2 μg/μl in NuPAGE® LDS Sample Buffer (Life Technologies, USA).
Samples were heated at 70 °C for 10 min and resolved on NuPAGE® 4–
12% Bis–Tris Gel using NuPAGE® MOPS SDS Running Buffer (Life Tech-
nologies, USA) at a constant voltage (200V, 60min). Proteinswere trans-
ferred onto nitrocellulose membranes, 0.45 μm (Millipore, USA).
Membranes were blocked with 5% non-fat dry milk in TBS-Tween
(20 mM Trizma base, 137 mM NaCl, 0.05% Tween, pH 7.6) for 1 h at
room temperature. After blocking, the membranes were incubated over-
night with primary antibodies diluted in 3% non-fat dry milk and TBS-
Tween. The membranes were probed with HRP-conjugated secondary
antibodies and developed by chemiluminescence (ECL Western Blotting
Detection Reagents; GE Healthcare, France). All antibodies used in this
study were commercially available and raised against the following anti-
gens: cleaved caspase-3 (rabbit polyclonal anti-cleaved caspase-3,
Asp175, 1:1000, Cell Signaling, 9661), LC3 (rabbit polyclonal anti-microtubule-associated protein 1A/1B-light chain 3, 1:1000, Novus Bio-
logicals, NB100-2220), α-fodrin (mouse monoclonal anti-α-fodrin,
1:3000, Enzo Life Sciences, AA6), glutamine synthetase (mousemonoclo-
nal anti-glutamine synthetase, clone GS-6, 1:1000, Millipore, MAB302),
NeuN (mouse monoclonal anti-NeuN clone A60, 1:750, Millipore,
MAB377), NFM (mouse monoclonal anti-NFM clone NF-09, 1:1000,
Santa Cruz, sc-51683), nonphosphorylated-NFM (mouse monoclonal
anti-NFM, clone RMO44, 1:1000, Invitrogen, 13-0500), GFAP (mouse
monoclonal anti-GFAP, 1:2500,Millipore,MAB360), actin (goat polyclon-
al anti-actin, clone I-19, 1:1000, Santa Cruz, sc1616), MRPL12 (rabbit
polyclonal anti-mitochondrial ribosomal protein L12, 1:3000,
Proteintech, 14795-1-AP). Secondary antibodies were HRP conjugated
goat anti-mouse, anti-rabbit or rabbit anti-goat IgG (Vector Laboratories).
Images were taken with a Luminescent Image Analyzer LAS-4000
(Fujiﬁlm; Life Science) and quantiﬁed with the public Java-based
image processing program ImageJ (National Institutes of Health). Data
acquired in arbitrary densitometric units were normalized to the refer-
ence protein and transformed to percentages of the densitometric levels
obtained from scans of control samples visualized on the same blots.
2.6. Glutamine synthetase activity
Frozen aggregates were thawed in 0.4 ml of 2 mM potassium phos-
phate containing 1 mM EDTA (pH 6.8), homogenized by sonication, di-
vided into aliquots and stored at−80 °C. Protein concentrations were
determined by the method of Lowry [27] using bovine serum albumin
as a standard. Glutamine synthetase (GS, EC 6.3.1.2) activity was
assayed by a modiﬁcation [28] of the method of Pishak and Phillips
[29]. L-[1-14C] glutamic acid was used as precursor, and phosphoenol-
pyruvate/pyruvate kinase as the ATP-regenerating system.
2.7. Basic metabolites and amino acids in culture media
200 μl of culture medium were taken for measurement of NH4+ and
were replaced with fresh culture medium. NH4+ was measured on an
Integra automatic analyzer (Roche, Switzerland); glucose and lactate
were measured on a Cobas 8000 (Roche, Switzerland); free amino
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scribed previously [24,30].
2.8. Intracellular glutamic acid and glutamine quantiﬁcation
Glutamic acid and glutamine were measured by isotope-dilution
high performance liquid chromatography coupled to high resolution
mass spectrometry (LC-MS HR), as described below. A stock solution
containing glutamic acid and glutamine at 0.35 mM in 0.1 N HCl was
prepared. The resulting stock solution was further diluted in 60 mg/ml
BSA in PBS to form the calibration solutions with ﬁnal concentrations
of 10, 20, 40, 60, 80 and 100 μM. An internal standard mix of 12 stable
isotopes including d3-glutamic acid (Cambridge Isotope Laboratories,
labeled amino acids set A) was used at a concentration of 1.25 mM in
0.1% (v/v) formic acid in water.
Calibration standards and samples (5 μl) were added to 45 μl of 0.1%
(v/v) formic acid and mixed with 250 μl of acetonitrile containing the
internal standards at a ﬁnal concentration of 5 μM in a 96 × 1 ml deep
well plate. After shaking for 10 min at 1200 rpm, the plate was incubat-
ed for 30min at−20 °C and centrifuged at 4000g at 4 °C for 30min. The
supernatants (200 μl) were transferred to a new 96-well plate, sealed,
and transferred to the LC-MS autosampler for analysis.
Chromatographic analysis was performed using an Accela pump
(Thermo Scientiﬁc) and a PAL System autosampler (Thermo Scientiﬁc,
CTC Analysis). Separation of the amino acids was achieved using an
Acquity UPLC®BEHAmide column (1.7 μm2.1mm×150mm,Waters).
The mobile phases consisted of H2O with 20 mM ammonium formate
and 0.1% (v/v) formic acid (mobile phase A), acetonitrile (mobile
phase B). The ﬂow rate was 400 μl/min throughout and the gradient in-
creased linearly from 5% A, 95% B to 40% A, 60% B within 20 min.0
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Fig. 2. Rapid extracellular NH4+ accumulation under 2-MCA exposure. NH4+ concentrations (
treatment until DIV 19 in controls, cultures treated with repeated doses of 0.1/0.33/1 mM 2-
(n= 3 or 4); Student's t-test: *p b 0.05, **p b 0.01, ***p b 0.001.Detection was performed using an orbitrap Q-Exactive mass spec-
trometer (Thermo Scientiﬁc). The instrument was equipped with an
electrospray interface and was controlled by Xcalibur software version
2.2 (Thermo Scientiﬁc). The samples were analyzed in the positive-ion-
izationmode in full scanmodewith a scan range from70 to 1000m/z, at
a resolution of 70,000.
Calibration curves were computed using the ratio of the peak area of
the amino acids glutamic acid and glutamine and their internal standard
d3-glutamic acid with a weighted (1/x) linear regression analysis.
2.9. Statistics
All data points are expressed as mean ± standard deviation (SD),
unless specify otherwise. Statistical difference was determined with
Student's t-test with p b 0.05.
3. Results
3.1. Rapid extracellular NH4
+ accumulation
NH4+ levels were measured from 6 h after the ﬁrst 2-MCA adminis-
tration (DIV 11) to DIV 19 (Fig. 2). The onset and degree of NH4+ accu-
mulation depended on the administered concentrations of 2-MCA.
NH4+ already rose signiﬁcantly 6 h after the ﬁrst 1 mM 2-MCA treat-
ment. For lower 2-MCA concentrations (0.1 and 0.33 mM) the NH4+ in-
crease started slightly later, 12 h after the ﬁrst treatment. The maximal
mean NH4+ concentrations measured in culture media after repeated 2-
MCA administrationwere 1748 μMonDIV 16 after exposure to 1mM2-
MCA, 984.5 μMonDIV 14with 0.33mM2-MCA, and 360.5 μMonDIV 12
with 0.1 mM 2-MCA. This represents up to 15 times of the NH4+4 DIV 15 DIV 16 DIV 17 DIV 18 DIV 19
-
0.33 
1.00  
1.00
0.10
2-MCA
[mM]
repeated
treatment
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dose
μM) were measured in culture medium at different time points, from 6 h after the ﬁrst
MCA, or cultures treated with a single dose of 1 mM 2-MCA. Data shown as mean ± SD
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maximal NH4+ concentration was reached earlier and started to drop
down earlier for lower concentrations of 2-MCA. The NH4+ level ob-
served on DIV 15 in cultures exposed to 1 mM 2-MCA is most probably
due to a dilution effect caused by the change of 5/8 ml of culture medi-
um on DIV 14, at a stage when aggregates continued to produce NH4+
under 2-MCA exposure. Five days after the end of 2-MCA administra-
tions (DIV 19) NH4+ levels were still signiﬁcantly higher for all concen-
trations compared to control cultures. A single dose of 1 mM 2-MCA
administered on DIV 11 also induced signiﬁcant NH4+ accumulation
with a similar time course, but the maximal NH4+ mean concentration
was reached onDIV 13 and stayed lower at 922 μMcompared to repeat-
ed administration of 1 mM 2-MCA (Fig. 2).
3.2. Decreased extracellular glutamine levels, increased intracellular gluta-
mine levels and glutamine synthetase activity
GS is themain enzyme responsible for NH4+ detoxiﬁcation in the CNS
through synthesis of glutamine in astrocytes. Therefore, we examined
GS activity and expression in aggregates and glutamine levels in culture
medium to see whether this pathway was affected by 2-MCA.
Glutamine levels in culture medium of treated aggregates were re-
duced compared to controls, starting from DIV 12 (Fig. 3A). The de-
crease of glutamine levels depended on the administered 2-MCA
concentrations. The lowest glutamine concentrations were observed
on DIV 14 for all concentrations. A single dose of 1 mM 2-MCA on DIV
11 also provoked a decrease of glutamine levels, which normalized on
DIV 15, earlier compared to repeated administration of 1 mM 2-MCA.
No other amino acid levels in culture medium were altered by 2-MCA
administration (data not shown).
GS activity was measured in aggregates on DIV 14. A 40% decrease
was observed after repeated administration of 1 mM 2-MCA (Fig. 3B).
Lower 2-MCA concentrations and a single dose of 1 mM 2-MCA did
not signiﬁcantly alter GS activity (data not shown). GS protein expres-
sion was also quantiﬁed by western blot. No signiﬁcant change was ob-
served between control and treated cultures (data not shown).
Intracellular glutamine measurements showed about two-fold in-
crease of glutamine content in 2-MCA treated aggregates (mean =
2122 μmol/L/g proteins, n = 2) compared to control aggregatesG
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3.3. Metabolic proﬁle
From DIV 11 to 13, no signiﬁcant difference was observed between
control and treated cultures regarding glucose and lactate levels in cul-
turemedium. OnDIV 14, as previously described [24], a decrease of glu-
cose was observed in cultures exposed repeatedly to 1 mM 2-MCA,
while a signiﬁcant increase of lactate was measured under repeated ex-
posure to 0.33 as well as 1 mM 2-MCA (Fig. 4). No other change in glu-
cose and lactate was found at lower 2-MCA concentrations as well as
with a single dose of 1 mM 2-MCA.
3.4. Morphological changes of developing brain cells
Aggregates were stained with different antibodies to identify brain
cell types and to examine how 2-MCA affected their morphology at dif-
ferent developmental stages.
The ﬁrst effects of 2-MCA on developing brain cells were already vis-
ible after 17 h on DIV 12. As previously described [24], a dose response
relationship was also observed in this study. Moreover, a single dose of
1 mM 2-MCA was already sufﬁcient to induce all observed morpholog-
ical alterations.
3.4.1. Astrocyte swelling
Astrocytes were already affected on DIV 12, 17 h after the ﬁrst ad-
ministration of the different 2-MCA concentrations. Swelling of astro-
cyte cell bodies and thickening of astrocyte ﬁbers increased
progressively over time until DIV 15. In aggregates exposed to 2-MCA,
there were areas devoid of GFAP staining, suggesting the loss of astro-
cytes in these areas (Fig. 5). On DIV 19, swollen astrocytes and thick ﬁ-
bers had disappeared; GFAPwas evenly localized along astrocytic ﬁbers
in controls and 2-MCA-treated aggregates at all 2-MCA concentrations
as shown by immunohistochemistry. Semi-quantitative determination
of GFAP by western blots did not reveal any signiﬁcant change in
GFAP expression, suggesting that the GFAP gene regulation was proba-
bly not affected by 2-MCA exposure. However, GFAP was a suitable
marker to follow the astrocytic morphological changes in 2-MCA-
0.33 
1.00  
1.00
0.10
2-MCA
[mM]
re
pe
at
ed
tre
at
m
en
t
si
ng
le
do
se
15 DIV 17 DIV 19
-
1.00  
2-MCA
[mM]
repeated 
treatment
levels [μM] were measured in culture medium from DIV 11 to DIV 19 in controls, cultures
f 1 mM 2-MCA. Data shown as mean ± SD (n= 3); Student's t-test: *p b 0.05, **p b 0.01,
ted aggregates harvested on DIV 14. Data shown as mean ± SD (n= 4).
-1.00  
1.00
0.10
2-MCA
[mM]
repeated treatment
single dose
0.33 
A
DIV 14
G
lu
co
se
 [m
M]
12
8
4
0
B
DIV 14
La
ct
at
e 
[m
M]
12
8
4
0
Fig. 4. Extracellular glucose and lactate levels on DIV 14. Glucose and lactate
concentrations [mM] were measured in culture medium from DIV 12 to 19 in controls,
cultures treated with repeated doses of 0.1/0.33/1 mM 2-MCA, or cultures treated with a
single dose of 1 mM 2-MCA. Data shown as mean ± SD (n = 3 to 7); Student's t-test:
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same morphological alterations were observed on DIV 14 and 15.3.4.2. Altered processing of neuroﬁlaments
Labeling of p-NFM showed protein retention in neuronal bodies of
aggregates exposed to 2-MCA compared to controls, starting on DIV
12. Reduced density of axonal ﬁbers was observed at more advanced
stages (Fig. 6). From DIV 15 to DIV 19, the difference between treated
and control aggregates was less pronounced. Western blot with anti-
bodies against total NFM, nonphosphorylated-NFM and NeuN did notFig. 5. Astrocyte swelling (arrow heads) and thickening of their primary ﬁbers (arrows) under
controls, cultures treated with repeated doses of 0.1/0.33/1 mM 2-MCA, or cultures treated wireveal any signiﬁcant change (data not shown). Similar effects were ob-
served in aggregates exposed to a single dose of 1 mM 2-MCA.
3.4.3. Delayed maturation of oligodendrocytes
Two different antibodies were used to identify oligodendrocytes.
When GalC, a marker for oligodendrocytes, was used, no change was
observed between treated and control aggregates. However, when
using MBP, a marker labeling myelin in more differentiated oligoden-
drocytes, a decrease of signal intensity was observed in all treated ag-
gregates from DIV 13 and persisted on DIV 19 (Fig. 7). This might
indicate a signiﬁcant effect of 2-MCA on oligodendrocyte maturation.
A single dose of 2-MCAwas sufﬁcient to induce a decrease ofMBP signal
intensity on DIV 14 and 15.
3.4.4. Microglia
Labeling of microglia with Isolectin IB4 did not reveal signiﬁcant
changes between controls and cultures exposed to different 2-MCAcon-
centrations (data not shown).
3.5. Highest apoptosis rate on DIV 14
Cleaved caspase-3 levels were examined in aggregates by immuno-
histochemistry (Fig. 8A) and western blot (Fig. 8B) from DIV 12 to DIV
19 to determine the time course of apoptosis under 2-MCA exposure.
No difference was observed between control and 2-MCA treated aggre-
gates on DIV 12 and 13. OnDIV 14 the highest levels of cleaved caspase-
3 were observed for all concentrations of 2-MCA and diminished pro-
gressively thereafter. As previously described [24], the increase of
cleaved caspase-3 levels depended on the administered concentration
of 2-MCA. But even a single dose of 1 mM 2-MCA was sufﬁcient to in-
duce an increase in cleaved caspase-3 at DIV 14.
Western blotting with an antibody against α-fodrin showed in-
creased levels of the caspase-3 cleaved fragment of α-fodrin on DIV 14
in 2-MCA treated aggregates compared to controls (Fig. 8C), which is
consistent with the ﬁndings above. In contrast, no changewas observed2-MCA exposure. Immunoﬂuorescence for GFAP on DIV 12, 14, 15, and 19 in astrocytes of
th a single dose of 1 mM 2-MCA. Scale bar: 100 μm.
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Fig. 6. p-NFM retention in neuronal cell bodies (arrows) and reduced density of axons
under 2-MCA exposure. Immunoﬂuorescence for p-NFM on DIV 14 in controls, cultures
treated with repeated doses of 0.1/0.33/1 mM 2-MCA or cultures treated with a single
dose of 1 mM 2-MCA. Left column: center of the aggregate cultures. Right column:
periphery of the aggregate cultures. Scale bar: 100 μm.
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Fig. 7.Delayedmyelination under 2-MCA exposure. Left column: Immunoﬂuorescence for
GalC on DIV 14 in oligodendrocytes of controls, cultures treated with repeated doses of
0.1/0.33/1 mM 2-MCA, or cultures treated with a single dose of 1 mM 2-MCA. No
difference was observed between controls and treated cultures. Right column:
Immunoﬂuorescence for MBP on DIV 14 in oligodendrocytes of controls, cultures treated
with repeated doses of 0.1/0.33/1 mM 2-MCA or cultures treated with a single dose of
1 mM 2-MCA. MBP expression was weaker in treated cultures as compared to controls.
Scale bar: 100 μm.
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Western blotting with an antibody against LC3, a marker for autophagy
that may result in cell death, did not reveal signiﬁcant differences be-
tween 2-MCA exposed aggregates and control aggregates (data not
shown).
3.6. Pan-caspase inhibitors do not prevent biochemical and morphological
changes
To analyze whether the 2-MCA-induced NH4+ accumulation preced-
ed the increase of apoptosis, we inhibited apoptosis using the pan-cas-
pase inhibitors Z-VAD FMK or Q-VD-OPh. Pan-caspase inhibitors were
administered at the same time as theﬁrst 2-MCA exposure. Immunoﬂu-
orescence and western blot with an antibody against cleaved caspase-3
showed that administration of these apoptosis inhibitors successfully
inhibited caspase-3 activation (Fig. 9A, B), thereby preventing the oc-
currence of apoptosis. Despite successful apoptosis inhibition, NH4+
still accumulated in culturemediumof treated aggregates (Fig. 9C). Glu-
tamine decrease (Fig. 9D) and morphological alterations (Fig. 9E) alsooccurred despite apoptosis inhibition. These ﬁndings indicate that apo-
ptosis per sewasnot the cause of either ammoniumaccumulation or the
observed morphological and biochemical changes.
4. Discussion
The aim of the present studywas to determine the time course of the
effects recently observed after 2-MCA exposure in 3D rat brain cells ag-
gregates under development [24].We particularly wanted to determine
the role of ammonium that was observed to accumulate in this in vitro
model for brain damage in MMAuria.
4.1. Increased production of NH4
+ precedes metabolic and morphological
alterations
The earliest observed event was NH4+ accumulation in culturemedi-
um of aggregates treated with 2-MCA. It started within few hours after
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rapidly after exposure to 2-MCA suggests that thismay be theﬁrst path-
ogenic event, triggering further cellular and metabolic responses. NH4+
accumulation can result from excessive production or reduced detoxiﬁ-
cation mechanisms. As the 3D rat brain cell aggregate model contains
exclusively brain cells and is a closed system, an alteration of the brain
cell metabolism must be responsible for the accumulation of NH4+.
Major pathways for cerebral NH4+ production are (i) glutaminase ac-
tivity, which converts glutamine to glutamate, (ii) glutamate dehydro-
genase (GDH), which catalyzes oxidative deamination of glutamate in
the astrocytes to release NH4+ for glutamine synthesis [31], and (iii)
the purine nucleotide cycle, which converts L-aspartate to fumarate
[32]. As organ, the brain is unable to detoxify NH4+ by producing urea
because it does not express the full enzyme set of urea cycle. Hence,
other reactions are responsible for NH4+ detoxiﬁcation in the brain.
The predominant one is the GS reaction, which converts brain NH4+ to
glutamine. The second pathway for cerebral NH4+ detoxiﬁcation is the
reductive amination of α-ketoglutarate by GDH, which catalyzesglutamate synthesis in the neuron in order to capture the NH4+ released
by phosphate-activated glutaminase [31]. The GS reaction leads to in-
creased concentration of glutamine, whereas the GDH reaction results
in increased concentration of alanine [32]. However, no change in gluta-
mate or alanine levels was observed in our model.
In this study, GS activity was reduced in aggregates exposed to 2-
MCA. As GS is mainly located in astrocytes [33], the reduced GS activity
could result from astrocytic suffering and/or astrocyte loss by apoptotic
cell death. Another possible explanation could be the induction of iNOS
(inducible nitric oxide synthase) expression by excessive NH4+ concen-
tration, since an increase in cerebral nitric oxide stimulates
peroxynitrite-mediated nitration of tyrosine residues of GS, resulting
in inactivation of GS [34]. Thereby, production of NO induced by NH4+
can inhibit GS and aggravate NH4+ accumulation [35,36].
We also observed that glutamine levels decreased in culture medi-
um and increased intracellularly after exposure of aggregates to 2-
MCA. Glutamine is considered as a mediator of NH4+ toxicity. According
to the so-called “Trojan Horse” hypothesis, glutamine can be
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yielding glutamate and NH4+. In this manner, glutamine serves as an
NH4+ carrier [37,38]. Thus, decreased glutamine in culture medium
could also be due to the glutamine sink intomitochondria, inwhich glu-
taminewould be converted to glutamate and NH4+. The fact that we did
not observe any glutamate increase intracellularly does not contradict
this hypothesis as excess glutamate inmitochondria can rapidly be con-
verted toα-ketoglutarate in order to feed the TCA cycle, thus producing
ammonium. However, seen the signiﬁcant intracellular glutamine in-
crease other mechanisms might be involved in its production.
Increased NH4+ levels are known to be toxic for the CNS. Moreover,
the consequences of NH4+ toxicity aremore devastating for a developing
than for an adult brain [39,40]. Indeed, NH4+ is known to play a role inastrocyte swelling, alterations of glutamatergic neurotransmission, ce-
rebral energy deﬁcit, alteration of nitric oxide synthesis, impairment
of axonal and dendritic growth, and cell death [40]. All these deleterious
effects have been evoked to explain the neuropathogenesis of MMAuria
[8,9,24].
4.2. 2-MCA induces astrocyte swelling, impairment of axonal growth and
delayed myelination
Astrocyte swelling is the most pronounced morphological change
observed under 2-MCA exposure, and it was already visible 17 h after
the ﬁrst exposure. Astrocytes are known to be prone to swelling in
many clinical conditions, including hyperammonemia and hepatic
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to astrocytic swelling remain elusive. It is proposed that NH4+-induced
oxidative stress initiates a cascade of events resulting in induction of
themitochondrial permeability transition and activation of intracellular
signaling kinases. These events ﬁnally lead to the inability of astrocytes
to regulate their intracellular volume, thus resulting in cell swelling
[42]. Moreover, increased glutamine content in astrocytes is thought
to be responsible for astrocyte swelling [40]. The decreased extracellular
glutamine and the intracellular increase of glutamine content seen in
our model could be responsible for astrocyte swelling.
Staining of aggregates treatedwith 2-MCAwith the antibody against
p-NFM suggest an impairment of axonal growth. This is in line with
neuroimaging ﬁndings in MMAuria patients, who often manifest ven-
tricular enlargement, cortical atrophy, periventricular white matter ab-
normalities, and thinning of the corpus callosum [43]. A previous study
in 3D rat brain cells aggregates showed that NH4+ exposure leads to de-
creased NFM expression and phosphorylation and inhibition of axonal
growth [44]. Moreover, astrocytes release several trophic factors
which can stimulate neurite outgrowth [45]. If astrocytes are suffering,
they might not be able to sustain axonal growth.
Interestingly, the morphological differences observed in astrocytes
and neurons were less signiﬁcant at the end of the experiment (DIV
19). This can be due to two different mechanisms: either the suffering
cells undergo cell death and disappear; or, they are able to recover.
Semi-quantitative determination of expression levels did not indicate
any signiﬁcant cell loss over time, thus making the hypothesis of recov-
ery more likely.
The decreased MBP signal in aggregates treated with 2-MCA sug-
gests a myelination delay, which is a common ﬁnding on brain imaging
of MMAuria patients [43]. Axonal myelination is inﬂuenced by astro-
cytes. It is known that astrocytes secrete factors that directly affect oli-
godendrocytes [25,46]. Experimental models of demyelination
demonstrated an important role for astrocytes in the subsequent
remyelination [25]. It was shown that oligodendrocytes cannot
myelinate demyelinated axons in areas devoid of astrocytes [47].
In conclusion, NH4+ accumulation in culturemediumof 2-MCA treat-
ed aggregates is a very early event, andmight be the cause of swelling of
astrocytes. Impairment of axonal outgrowth and delayed myelination
might be secondary effects determined by dysfunction of astrocytes.
4.3. 2-MCA increases the apoptotic rate
2-MCA exposure signiﬁcantly increased cleaved caspase-3 levels in
ourmodel. Cleaved caspase-3 ismainly known to be a key protein in ap-
optosis execution. It has been shown in 3D brain cell cultures that NH4+
induced cell death by apoptosis [48]. Our data suggest that increased
NH4+ concentrations might cause apoptosis in aggregates exposed to
2-MCA.
4.4. A single dose of 2-MCA is sufﬁcient to induce deleterious damage
The second aim of this study was to compare the toxicity of a single
dose of 1 mM 2-MCA with that observed with multiple doses.
Due to its low prevalence, MMAuria is often misrecognized. This
leads to delay in diagnosis and introduction of appropriate treatment.
Therefore, irreversible brain damage might already be present at diag-
nosis. In some countries,MMAuria is part of the newborn screeningpro-
gram. Thus, affected patients could be treated pre-symptomatically and
avoid severe sequels. However, some patients still manifest neurologic
impairment in spite of early diagnosis [49].
The “repeated treatment” protocol applied in this studymimics a sit-
uationwith increasing amounts of circulatingmetabolites during sever-
al days. This situation might represent an undiagnosed MMAuria
patient with delayed diagnosis and treatment after the onset of symp-
toms. Meanwhile, the toxic metabolites continue to accumulate until
the appropriate treatment is introduced. On the other hand, the “singledose” treatment protocol reﬂects the situation of a well-known patient
undergoing a febrile infection with prompt initiation of emergency
treatment. Both situations were compared to evaluate their impact on
brain injuries.
A single dose of 1 mM 2-MCA was found to be sufﬁcient to induce
deleterious effects in 3D rat brain cell aggregates. This result is in line
with the clinical observation that brain damage can occur in known
MMAuria patients suffering a metabolic decompensation despite early
introduction of adequate treatment.
5. Conclusions and perspectives
This study shows that ammonium accumulation is an early and pri-
mary effect of 2-MCA exposure in our in vitromodel for brain damage in
MMAuria. As a second signiﬁcant result, we now can exclude that am-
monium accumulation is the consequence of signiﬁcant cell death by
apoptosis, as ammonium increased in the samemanner after inhibition
of apoptosis. Finally, a single dose of 1mM2-MCAwas as efﬁcient in in-
ducing ammonium accumulation and cytopathologic changes as a
prolonged exposure. If translated to the in vivo situation of patients af-
fected by MMAuria or propionic aciduria, this might imply that during
a catabolic state, an increase of 2-MCA in the brainmight rapidly induce
intracerebral NH4+ accumulation. This early event could be the trigger
for other biochemical and morphological alterations, including cell
death by apoptosis, suggesting a potential danger for brain damage in
everymetabolic decompensation, even for short duration, once a critical
threshold of intracerebral 2-MCA concentrations has been passed. Fur-
ther studies should focus on the elucidation of the biochemical path-
ways leading to NH4+ accumulation in our model and verify if this
observation obtained can be conﬁrmed in vivo. A deeper understanding
of the implicated pathways might give us indications for the develop-
ment of neuroprotective strategies in MMAuria.
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